IQVIA Holdings Aktie
201,77USD | 4,20USD | 2,13% |
WKN DE: A2JSPM / ISIN: US46266C1053
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 99,18 |
The Vanguard Group, Inc. | 11,56 |
Vanguard Group, Inc. (Subfiler) | 10,55 |
Harris Associates LP | 5,58 |
Harris Associates LP | 5,35 |
GIC Pte Ltd. (Investment Management) | 5,01 |
State Street Corp. | 4,26 |
BlackRock Fund Advisors | 3,44 |
Vanguard Total Stock Market ETF | 3,00 |
Vanguard 500 Index Fund | 2,52 |
Geode Capital Management LLC | 2,25 |
AllianceBernstein LP | 2,14 |
BlackRock Institutional Trust Co. NA | 2,11 |
Vanguard Mid Cap Index Fund | 2,02 |
Canada Pension Plan Investment Board | 1,96 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 67 000 | 70 000 | 79 000 | 86 000 | 87 000 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,17 | 0,16 | 0,18 | 0,17 | 0,17 |
Bilanz (in Mio. USD) - Aktiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 4 126 | 5 090 | 4 763 | 4 981 | 5 596 |
Summe Anlagevermögen | 19 125 | 19 474 | 19 926 | 20 356 | 21 085 |
Summe Aktiva | 23 251 | 24 564 | 24 689 | 25 337 | 26 681 |
Bilanz (in Mio. USD) - Passiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Gesamtverschuldung/ -verbindlichkeiten | 12 194 | 13 182 | 12 764 | 13 351 | 14 231 |
Summe Fremdkapital | 16 988 | 18 284 | 18 647 | 19 572 | 20 569 |
Summe Eigenkapital | 6 263 | 6 280 | 6 042 | 5 765 | 6 112 |
Summe Passiva | 23 251 | 24 564 | 24 689 | 25 337 | 26 681 |
Adresse
2400 Ellis Road, 27703 Durham | |
Telefon | +1 (919) 998-2000 |
Internet | http://www.iqvia.com |
Management
Ari Bousbib
Chairman, President & Chief Executive Officer |
Carol J. Burt
Independent Director |
Colleen A. Goggins
Independent Director |
Eric M. Sherbet
Secretary, Executive VP & General Counsel |
James A. Fasano
Independent Director |
James Grant Berkshire
Executive VP-Global Technology & Operations |
Jeffrey A. Spaeder
Chief Medical & Scientific Officer |
Joanne M. Hackett
Head-Genomic & Precision Medicine |
John G. Danhakl
Independent Director |
John M. Leonard
Lead Independent Director |
John P. Connaughton
Independent Director |
Karl Guenault
Chief Information Officer & Senior Vice President |
Keriann Cherofsky
Chief Accounting Officer, Senior VP & Controller |
Leslie Wims Morris
Independent Director |
Michael Stibilj
Vice President-Global Delivery Network |
Nick Childs
SVP-Investor Relations & Treasury |
Ronald Earl Bruehlman
Chief Financial Officer & Executive Vice President |
Sanjay Chikarmane
Chief Product Officer |
Sheila A. Stamps
Independent Director |
Todd Benjamin Sisitsky
Independent Director |
Trudy Stein
Chief Human Resources Officer & Executive VP |
W. Richard Staub
President-Research & Development Solutions |